News
ExxonMobil and Scepter, Inc. to Deploy Satellite Technology for Real-Time Methane Emissions Detection
ExxonMobil and Scepter, Inc. have agreed to work together to deploy advanced satellite technology and proprietary data processing platforms to detect methane emissions at a global scale. The
Form 8.3 - The Vanguard Group, Inc.: NortonLife Lock Inc.
Form 8.3 - The Vanguard Group, Inc.: NortonLife Lock Inc.
Pfizer to Acquire Arena Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical
Pfizer to Acquire Arena Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical
DGAP-News: GEA Group Aktiengesellschaft: Eine Kapitalmartkinformation
DGAP-News: GEA Group Aktiengesellschaft: A Capital Market Information
DGAP-News: Deutsche Wohnen SE: CFO Philip Grosse wechselt zur Vonovia
DGAP-News: Deutsche Wohnen SE: CFO Philip Grosse joins Vonovia
Eurofins Technologies bringt den neuen Lateral-Flow-Reader RapidScan ST5-W - die einzige für mehrere Lebensmittel- und Umweltschnelltests verifizierte Plattform - auf den Markt
Eurofins Technologies (Paris:ERF), ein Anbieter von Testkits und Systemen für Laboranalysen, gibt die Markteinführung seines neuen Lateral-Flow-Readers RapidScan ST5-W bekannt, der speziell für
Für neun von zehn Versicherern in Europa ist bessere Kundenerfahrung Top-Treiber der digitalen Transformation
Die Nachfrage nach besseren Kundenerlebnissen ist der Haupttreiber für die digitale Transformation in der europäischen Versicherungswirtschaft. Doch parallel zum Fortgang der Digitalisierung nehmen
Nine in 10 Insurance Leaders in Europe Say Customer Experience is the Top Driver of Digital Transformation
Demand for improved customer experience is the top driver of digital transformation in Europe’s insurance industry, but with growing digitalization, insurers report increasing security
Northern Trust Launches New Climate Focus Reporting
Northern Trust (Nasdaq: NTRS) has further enhanced its suite of environmental, social and governance (ESG) investment analytics to deliver new climate risk reporting for global institutional
Northern Trust Launches New Climate Focus Reporting
Northern Trust (Nasdaq: NTRS) has further enhanced its suite of environmental, social and governance (ESG) investment analytics to deliver new climate risk reporting for global institutional
DGAP-News: Vonovia SE: Vonovia SE expands Management Board
DGAP-News: Vonovia SE: Vonovia SE erweitert Vorstand
Eurofins Technologies launches new Lateral Flow Reader RapidScan ST5-W as a single platform validated for multiple food and environmental rapid tests
Eurofins Technologies (Paris:ERF), a supplier of test kits and systems for laboratory analyses, announces the launch of its new RapidScan ST5-W lateral flow reader, specifically designed for field
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys präsentiert neueste Daten der MANIFEST Phase 2-Studie zur Bewertung des Potenzials von Pelabresib bei der Behandlung von Myelofibrose
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis